Similar articles for PMID: 22361422

Year	Number of Results
1995	1
1997	1
1999	2
2000	1
2001	2
2002	2
2004	5
2008	1
2009	6
2010	6
2011	5
2012	8
2013	5
2014	4
2015	13
2016	5
2017	2
2018	3
2019	1
2020	1
2022	1
2023	2
2024	0

1

MDR tuberculosis and non-compliance with therapy.

Cox H, Hughes J, Ford N, London L. Cox H, et al. Lancet Infect Dis. 2012 Mar;12(3):178; author reply 178-9. doi: 10.1016/S1473-3099(12)70011-7. Lancet Infect Dis. 2012. PMID: 22361422 No abstract available.

2

MDR tuberculosis and non-compliance with therapy.

Ereqat S, Spigelman M, Bar-Gal GK, Ramlawi A, Abdeen Z. Ereqat S, et al. Lancet Infect Dis. 2011 Sep;11(9):662. doi: 10.1016/S1473-3099(11)70227-4. Lancet Infect Dis. 2011. PMID: 21867955 No abstract available.

3

Multidrug resistant TB: fully oral regimens should help improve compliance, says WHO.

Murphy D. Murphy D. BMJ. 2018 Aug 21;362:k3610. doi: 10.1136/bmj.k3610. BMJ. 2018. PMID: 30131439 No abstract available.

4

Expanding the evidence base supporting shorter treatment durations for multidrug-resistant tuberculosis.

Nuermberger E, Yew WW. Nuermberger E, et al. Int J Tuberc Lung Dis. 2015 May;19(5):497-8. doi: 10.5588/ijtld.15.0110. Int J Tuberc Lung Dis. 2015. PMID: 25868013 No abstract available.

5

Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant Tuberculosis.

Pasipanodya J, Srivastava S, Gumbo T. Pasipanodya J, et al. J Infect Dis. 2015 Jul 1;212(1):166-7. doi: 10.1093/infdis/jiv068. Epub 2015 Feb 3. J Infect Dis. 2015. PMID: 25649174 No abstract available.

6

Effects of treatment interruption patterns on treatment success among patients with multidrug-resistant tuberculosis in Armenia and Abkhazia.

Bastard M, Sanchez-Padilla E, Hewison C, Hayrapetyan A, Khurkhumal S, Varaine F, Bonnet M. Bastard M, et al. J Infect Dis. 2015 May 15;211(10):1607-15. doi: 10.1093/infdis/jiu551. Epub 2014 Oct 13. J Infect Dis. 2015. PMID: 25312040

7

Adherence and acquired drug-resistance in tuberculosis: wisdom stood on its head.

Kadhiravan T. Kadhiravan T. Indian J Chest Dis Allied Sci. 2013 Jan-Mar;55(1):9-10. Indian J Chest Dis Allied Sci. 2013. PMID: 23798083 No abstract available.

8

Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?

Bastard M, Bonnet M, du Cros P, Khamraev AK, Hayrapetyan A, Kimenye K, Khurkhumal S, Dlamini T, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F. Bastard M, et al. Am J Respir Crit Care Med. 2015 Feb 1;191(3):355-8. doi: 10.1164/rccm.201407-1302LE. Am J Respir Crit Care Med. 2015. PMID: 25635495 No abstract available.

9

Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?

Gupta R, Raviglione MC, Espinal MA. Gupta R, et al. Int J Tuberc Lung Dis. 2001 Dec;5(12):1078-9. Int J Tuberc Lung Dis. 2001. PMID: 11769764 Review. No abstract available.

10

Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?

Coker R. Coker R. Int J Tuberc Lung Dis. 2002 Aug;6(8):649-50. Int J Tuberc Lung Dis. 2002. PMID: 12150473 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

73 results

Results by year